Two-year results of the CoreValve US Pivotal trial reported at TCT 2014

Clinical trial examines the long term outcomes of a self-expanding transcatheter aortic valve in inoperable patients with aortic stenosis

2014-09-15

(Press-News.org) WASHINGTON, DC – September 13, 2014 – In extended follow-up from a clinical trial, a self-expanding transcatheter aortic valve was shown to have low rates of all-cause mortality and major stroke. Findings were reported today at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

Degenerative aortic stenosis is a progressive disease with a poor prognosis in the absence of surgical aortic valve replacement. For patients at extreme risk for surgical complications, transcatheter aortic valve technologies offer a less invasive option of therapy for aortic stenosis. Previous trials have shown that a self-expanding transcatheter aortic valve was associated with low rates of all-cause mortality and major stroke at one year, but the long term effects of this device are unknown.

The CoreValve US Pivotal was a prospective, non-randomized single-arm, multicenter trial to determine the safety and efficacy of self-expanding TAVR at two-years in patients at extreme risk for surgery. The primary endpoint was a composite of all-cause mortality or major stroke rate at 12 months. Efficacy and safety outcomes at two years were also examined.

The study enrolled a total of 489 patients undergoing transfemoral self-expanding TAVR deemed to be at extreme risk for surgery. The one-year rate of all-cause mortality or major stroke was 26.0 percent (all-cause mortality, 24.3 percent; major stroke 4.3 percent). After two years, the rate of all-cause mortality or major stroke was 38.0 percent. Both one and two year rates of adverse outcomes compared favorably with historical performance criteria established among medically managed patients with aortic stenosis. Patients treated with the self-expanding TAVR device also reported improvement in NYHA classifications, durable improvement in hemodynamic valve performance, and low rates of moderate or severe aortic insufficiency.

"The first year results from the CoreValve US Pivotal Trial support the safety and efficacy of this therapy in patients unsuitable for surgical aortic valve replacement," said lead investigator Steven Yakubov, MD. Dr. Yakubov is Medical Director, OhioHealth Research Foundation at OhioHealth.

"The two-year results confirm the improved survival benefit in these patients."

INFORMATION: The CoreValve US Pivotal trial was funded by Medtronic. Dr. Yakubov reported no disclosures.

The results of the CoreValve US Pivotal trial will be presented on Saturday, September 13 at 12:00 PM EDT in the Main Arena (Level 3, Ballroom) of the Walter E. Washington Convention Center.

About CRF and TCT The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with heart disease through high quality research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. For more than 25 years, TCT has featured major medical research breakthroughs and gathered leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.

For more information, visit http://www.crf.org and http://www.tctconference.com.

ELSE PRESS RELEASES FROM THIS DATE:

Results of ISAR-CLOSURE trial reported at TCT 2014

2014-09-15

WASHINGTON, DC – September 13, 2014 – A new clinical trial found that vascular closure devices (VCD) are non-inferior to manual compression in patients undergoing transfemoral coronary angiography. Findings were reported today at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. Vascular closure devices help achieve more rapid hemostasis after coronary angiography, however ...

International study identifies new genetic variants indicating risk for prostate cancer

2014-09-15

An international study co-led by Keck School of Medicine of the University of Southern California (USC) scientists and researchers in the United Kingdom has revealed 23 new genetic susceptibility locations indicating risk for prostate cancer. The data study, analyzing more than 87,000 individuals of European, African, Japanese and Latino ancestry, is the largest of its kind and is the first that combines multiple studies across different ethnic populations. "The goal of this research is to identify regions of the genome that contribute susceptibility to prostate cancer ...

Contaminated water in 2 states linked to faulty shale gas wells

2014-09-15

DURHAM, N.C. -- Faulty well integrity, not hydraulic fracturing deep underground, is the primary cause of drinking water contamination from shale gas extraction in parts of Pennsylvania and Texas, according to a new study by researchers from five universities. The scientists from Duke, Ohio State, Stanford, Dartmouth and the University of Rochester published their peer-reviewed study Sept. 15 in the Proceedings of the National Academy of Sciences. Using noble gas and hydrocarbon tracers, they analyzed the gas content of more than 130 drinking water wells in the two ...

Gut bacteria tire out T cells

2014-09-15

Leaky intestines may cripple bacteria-fighting immune cells in patients with a rare hereditary disease, according to a study by researchers in Lausanne, Switzerland. The study, published in The Journal of Experimental Medicine on September 15, may explain why these patients suffer from recurrent bacterial infections. Patients with a disease called common variable immunodeficiency (CVID) suffer from recurrent bacterial infections as a result of faulty immune cells. But despite these immune defects, CVID patients rarely contract viral infections. New data from Matthieu ...

T-bet tackles hepatitis

2014-09-15

A single protein may tip the balance between ridding the body of a dangerous virus and enduring life-long chronic infection, according to a report appearing in The Journal of Experimental Medicine. Hepatitis B and C viruses cause chronic infections in roughly three-quarters of infected people, putting these individuals at risk for developing liver diseases including cirrhosis and cancer. A few patients successfully eliminate infection, thanks primarily to virus-fighting immune cells called CD8+ T cells. The protective effects of CD8+ T cells depend on a cellular protein ...

Gas leaks from faulty wells linked to contamination in some groundwater

2014-09-15

COLUMBUS, Ohio—A study has pinpointed the likely source of most natural gas contamination in drinking-water wells associated with hydraulic fracturing, and it's not the source many people may have feared. What's more, the problem may be fixable: improved construction standards for cement well linings and casings at hydraulic fracturing sites. A team led by a researcher at The Ohio State University and composed of researchers at Duke, Stanford, Dartmouth, and the University of Rochester devised a new method of geochemical forensics to trace how methane migrates under ...

Rice rolls 'neat' nanotube fibers

2014-09-15

The very idea of fibers made of carbon nanotubes is neat, but Rice University scientists are making them neat -- literally. The single-walled carbon nanotubes in new fibers created at Rice line up like a fistful of uncooked spaghetti through a process designed by chemist Angel Martí and his colleagues. The tricky bit, according to Martí, whose lab reported its results this month in the journal ACS Nano, is keeping the densely packed nanotubes apart before they're drawn together into a fiber. Left to their own devices, carbon nanotubes form clumps that are perfectly ...

1 in 5 men reports violence toward intimate partners

2014-09-15

ANN ARBOR, Mich. —One in five men in the U.S. reports violence towards their spouse or significant other, says a new nationally-representative study by the University of Michigan. The analysis also found that male aggression toward a partner is associated with warning signs that could come up during routine health care visits, including irritable bowel syndrome (IBS) and insomnia, in addition to better known risks like substance abuse and a history of either experiencing or witnessing violence as a child. The findings appear in the Journal of the American Board of Family ...

UChicago study finds young women involve parent in abortion when anticipating support

2014-09-15

CHICAGO, IL—When an adolescent wants to terminate a pregnancy, how does she decide whether to talk to a parent? A recent study from the Section of Family Planning and Contraceptive Research at the University of Chicago found that pregnant teens will turn to parents and adults who are engaged in their lives and who will offer support, regardless of her pregnancy decision. Young women will avoid talking with parents who are less involved or may try to prevent them from seeking care. The study, published online ahead of print in the American Journal of Public Health, explored ...

Genetics reveals patients susceptible to drug-induced pancreatitis

2014-09-15

Doctors have discovered that patients with a particular genetic variation are four times more likely to develop pancreatitis if they are prescribed a widely used group of drugs. Clinicians at the Royal Devon and Exeter NHS Foundation Trust and the University of Exeter Medical School have discovered that 17 per cent of patients who have two copies of a particular genetic marker are likely to go on to develop pancreatitis if they are prescribed thiopurine drugs. The drugs, which include azathioprine and mercaptopurine, are some of the most effective and most commonly used ...

Two-year results of the CoreValve US Pivotal trial reported at TCT 2014

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: